Puma Biotech (PBYI) Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of three abstracts on neratinib for the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8, 2021. Puma will present three posters with audio recordings, the corresponding abstracts of which are now live on the 2021 ASCO Annual Meeting website. The full posters will be available on the Puma and ASCO websites at approximately 9:00 a.m. EDT on June 4, 2021.

Poster Session: Breast Cancer—Local/Regional/Adjuvant

• Abstract 540: Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial.
  B Moy, M Takahashi, S Ohtani, E Chmielowska, N Yamamoto, B Coudert, F Xu, A Wong, A Chan

• Abstract 536: Dose escalation for mitigating diarrhea: Ranked tolerability assessment of antidiarrheal regimens in patients receiving neratinib for early-stage breast cancer.
  G Marx, AJ Chien, JA García-Sáenz, A Chan, M Ruiz-Borrego, CH Barcenas, M Thirlwell, M Trudeau, R Bose, D Egle, B Pistilli, J Wasserman, KA Cheong, D Semsek, C Singer, D Hunt, U Khambholja, F Xu, N Shah, A Brufsky

Poster Session: Lung Cancer—Non-Small Cell Metastatic

• Abstract 9068: Neratinib efficacy in a subgroup of patients with EGFR exon 18-mutant non-small cell lung cancer (NSCLC) and central nervous system (CNS) involvement: findings from the SUMMIT basket trial.
  JW Goldman, SV Ramírez, A Mahipal, JM Suga, LD Eli, AS Lalani, R Bryce, F Xu, N Shah, F Kabbinavar, V Boni, B Haley

The abstracts are available online at: asco.org/abstracts

You May Also Be Interested In

• Hepion Pharmaceuticals (HEPA) Winds Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
• Vertex Pharma (VRTX) Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
• Benitec Biopharma (BNTC) Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301